Literature DB >> 16461848

Beta2-adrenoceptor genotype and function affect hemodynamic profile heterogeneity in postural tachycardia syndrome.

Giris Jacob1, Emily M Garland, Fernando Costa, C Michael Stein, Hong-Guang Xie, Rose Marie Robertson, Italo Biaggioni, David Robertson.   

Abstract

Previous studies suggest that the beta2-adrenoceptor functions abnormally in patients with postural tachycardia syndrome (POTS) and may contribute to their altered hemodynamic profile. To test the hypothesis that the beta2-adrenoceptor response is decreased in POTS, we studied: (1) the arterial vasodilation response to the beta agonist, isoproterenol, and (2) the distribution of common polymorphisms (codons 16 and 27) of the gene coding the receptor (beta2-AR) in a large population with POTS. We measured plasma catecholamines and monitored hemodynamics and changes in forearm and leg blood flow to incremental doses of intraarterial isoproterenol in 9 patients with POTS compared with 8 healthy subjects. For polymorphism assessment we collected DNA from 57 patients with POTS and compared with 67 age-sex matched healthy subjects. Circulating catecholamines were significantly higher in POTS subjects compared with controls. Intrabrachial and intrafemoral isoproterenol infusion elicited a dose-dependent increase in blood flow. In healthy subjects, blood flow increased (mean+/-SEM) 400+/-70% in the forearm and 170+/-40% in the leg, but only 280+/-60% in forearms and 120+/-20% in legs of patients with POTS (ANOVA for both P<0.001). The genotype and allele distributions for codons 16 and 27 beta2-AR variants were not different in the 2 groups. However, the blood pressure and plasma norepinephrine levels diverged in patients according to their genotype. Patients with Gly16Gly and patients with Glu27Glu had lower plasma catecholamines and higher supine and upright blood pressure, compared with other genotypes. Therefore, both decreased beta2-adrenoceptor-related vasodilation and beta2-AR polymorphisms may contribute to the hemodynamic diversity of patients with POTS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16461848     DOI: 10.1161/01.HYP.0000205120.46149.34

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  6 in total

1.  All that shine is not gold: modelling the true relation between orthostatic intolerance, fibromyalgia and chronic fatigue syndromes.

Authors:  Juvenia Bezerra Fontenele; Luzia Kalyne A M Leal; Francisco Hélder Cavalcante Félix
Journal:  Clin Auton Res       Date:  2008-12       Impact factor: 4.435

Review 2.  Hereditary determinants of human hypertension: strategies in the setting of genetic complexity.

Authors:  Pei-an Betty Shih; Daniel T O'Connor
Journal:  Hypertension       Date:  2008-04-14       Impact factor: 10.190

3.  β-1 and β-2 adrenergic receptor polymorphism and association with cardiovascular response to orthostatic screening.

Authors:  E D Wittwer; Z Liu; N D Warner; D R Schroeder; A M Nadeau; A R Allen; C J Murillo; R L Elvebak; B M Aakre; J H Eisenach
Journal:  Auton Neurosci       Date:  2011-07-31       Impact factor: 3.145

Review 4.  Postural tachycardia syndrome: a heterogeneous and multifactorial disorder.

Authors:  Eduardo E Benarroch
Journal:  Mayo Clin Proc       Date:  2012-11-01       Impact factor: 7.616

5.  Regulation of β-adrenergic control of heart rate by GTP-cyclohydrolase 1 (GCH1) and tetrahydrobiopterin.

Authors:  David Adlam; Neil Herring; Gillian Douglas; Joseph P De Bono; Dan Li; Edward J Danson; Amy Tatham; Cheih-Ju Lu; Katie A Jennings; Stephanie J Cragg; Barbara Casadei; David J Paterson; Keith M Channon
Journal:  Cardiovasc Res       Date:  2012-01-11       Impact factor: 10.787

6.  Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1.

Authors:  Steven Vernino; Kate M Bourne; Lauren E Stiles; Blair P Grubb; Artur Fedorowski; Julian M Stewart; Amy C Arnold; Laura A Pace; Jonas Axelsson; Jeffrey R Boris; Jeffrey P Moak; Brent P Goodman; Kamal R Chémali; Tae H Chung; David S Goldstein; Andre Diedrich; Mitchell G Miglis; Melissa M Cortez; Amanda J Miller; Roy Freeman; Italo Biaggioni; Peter C Rowe; Robert S Sheldon; Cyndya A Shibao; David M Systrom; Glen A Cook; Taylor A Doherty; Hasan I Abdallah; Anil Darbari; Satish R Raj
Journal:  Auton Neurosci       Date:  2021-06-05       Impact factor: 2.355

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.